The companies — Acumen, Dovel Technologies and IQVIA Government Solutions — were each given initial five-year contracts valued at $75 million to provide data and tools for the FDA’s Biologics Effectiveness and Safety Initiative, a program that aims to boost the safety and effectiveness of “vaccines, blood and blood products, tissues, and advanced therapeutics.”
Under the deal, the companies will help develop infrastructure that provides “data sources and the capability and capacity to run queries and observational studies on the data sources for [Center for Biologics Evaluation and Research]-regulated biologic products.” They will also help devise a network to analyze large-scale healthcare data.
More articles on supply chain:
AT&T, Merck pilot drones to deliver medical supplies to Puerto Rico
Intermountain recognizes 2018 Supplier Award winners
Walgreens to sell EpiPen alternative amid shortage
